{"url_path":"/sec/bdpt/10-q/2026/item-3","section_key":"item-3","section_title":"Item 3 Defaults Upon Senior Securities    **","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1575142/0001640334-26-000911-index.html","accession_number":"0001640334-26-000911","cik":"0001575142","ticker":"BDPT","issuer_name":"BIOADAPTIVES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1575142/0001640334-26-000911-index.html","primary_entity_key":"0001575142","primary_entity_name":"BIOADAPTIVES, INC."},"word_count":107,"has_tables":true,"body_markdown":"**Item 3. Defaults Upon Senior Securities    **\n\n \n\nThe Company has no senior securities, but has outstanding instruments previously characterized as unsecured convertible debentures.  These instruments are not senior to any other Company obligation.  The Company arranged extension and forbearance agreements with the holders of the 12% Debentures, which were issued in 2018 and were due at various times in 2020.  Our agreement called for the extension of these obligations on the same terms until December 31, 2021, in exchange for current interest payments and delivery of 280,000 shares of its common stock (total).  We are currently in default on these obligations but are working on an alternative resolution."}